                         SEQUENCE LISTING

<110>  Berkeley Lights, Inc.
 
<120>  Methods for Identification of Exchangeable MHC Binding Peptides 
       and Methods of Use Thereof

<130>  01149-0020-00PCT

<140>  PCT/US2021/062775
<141>  2021-12-10

<150>  US 63/124,606
<151>  2020-12-11

<150>  US 63/226,476
<151>  2021-07-28

<160>  70    

<170>  PatentIn version 3.5

<210>  1
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  1

Gly Met Gly Gln Lys Asp Ser Tyr Val 
1               5                   


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  2

Arg Met Gln Lys Glu Ile Thr Ala Leu 
1               5                   


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  3

Gln Leu Ala Lys Leu Met Ala Thr Leu 
1               5                   


<210>  4
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  4

Leu Met Tyr Ala Lys Arg Ala Phe Val 
1               5                   


<210>  5
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  5

Ser Leu Tyr Ser Tyr Phe Gln Lys Val 
1               5                   


<210>  6
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  6

Ser Leu Leu Pro Ile Met Trp Gln Leu Tyr 
1               5                   10  


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tumor associated antigen

<400>  7

Glu Leu Ala Gly Ile Gly Ile Leu Thr Val 
1               5                   10  


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tumor associated antigen

<400>  8

Ser Leu Leu Met Trp Ile Thr Gln Val 
1               5                   


<210>  9
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Elastin Like Peptide (ELP)


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is a variable amino acid which can modulate the effects of 
       the motif

<400>  9

Val Pro Gly Xaa Gly 
1               5   


<210>  10

<400>  10
000

<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  11

Ile Met Ala Leu Lys Gln Ala Gly Leu 
1               5                   


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  12

Phe Leu Ala Ile Lys Leu Tyr Val Gly 
1               5                   


<210>  13
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  13

Gly Ala Ala Thr Lys Met Ala Ala Val 
1               5                   


<210>  14
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  14

Gln Leu Ala Leu Lys Lys Val Glu Gly Val 
1               5                   10  


<210>  15
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  15

Ile Met Ala Leu Lys Lys Gln Ala Gly Leu 
1               5                   10  


<210>  16
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  16

Phe Leu Ala Ile Lys Lys Leu Tyr Val Gly 
1               5                   10  


<210>  17
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  17

Thr Glu Ile Gly Lys Asp Val Ile Gly Leu 
1               5                   10  


<210>  18
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Exemplary initial peptide sequence

<400>  18

Ile Leu Lys Glu Lys Lys Val His Val Gly 
1               5                   10  


<210>  19
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  FITC label

<400>  19

Gly Met Gly Gln Lys Asp Ser Tyr Val 
1               5                   


<210>  20
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  FITC label

<400>  20

Arg Met Gln Lys Glu Ile Thr Ala Leu 
1               5                   


<210>  21
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  FITC label

<400>  21

Ile Met Ala Leu Lys Gln Ala Gly Leu 
1               5                   


<210>  22
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  FITC label

<400>  22

Phe Leu Ala Ile Lys Leu Tyr Val Gly 
1               5                   


<210>  23
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  FITC label

<400>  23

Gly Ala Ala Thr Lys Met Ala Ala Val 
1               5                   


<210>  24
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  FITC label

<400>  24

Gln Leu Ala Leu Lys Lys Val Glu Gly Val 
1               5                   10  


<210>  25
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  FITC label

<400>  25

Ile Met Ala Leu Lys Lys Gln Ala Gly Leu 
1               5                   10  


<210>  26
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  FITC label

<400>  26

Phe Leu Ala Ile Lys Lys Leu Tyr Val Gly 
1               5                   10  


<210>  27
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  FITC label

<400>  27

Thr Glu Ile Gly Lys Asp Val Ile Gly Leu 
1               5                   10  


<210>  28
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Labelled peptide structure


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  FITC label

<400>  28

Ile Leu Lys Glu Lys Lys Val His Val Gly 
1               5                   10  


<210>  29

<400>  29
000

<210>  30

<400>  30
000

<210>  31
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  31

Tyr Thr Val Lys Phe Ala Leu Val 
1               5               


<210>  32
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  32

Met Thr Tyr Lys Phe Pro Val Thr 
1               5               


<210>  33
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  33

Gln Ile Pro Thr Lys Leu Ala Ala 
1               5               


<210>  34
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  34

Phe Leu Gln Glu Lys Ser Pro Ala Val 
1               5                   


<210>  35
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  35

Phe Leu Ala Ile Lys Leu Tyr Gly Val 
1               5                   


<210>  36
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  36

Phe Leu Leu Asp Lys Lys Ile Gly Val 
1               5                   


<210>  37
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  37

Ala Leu Trp Ala Lys Ser Pro Gly Val 
1               5                   


<210>  38
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  38

Phe Leu Leu Glu Lys Ser Arg Val Val 
1               5                   


<210>  39
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  39

Tyr Leu Ser Glu Lys Val Leu Ala Ala 
1               5                   


<210>  40
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  40

Phe Leu Ala Val Lys Pro Asp Gly Val 
1               5                   


<210>  41
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  41

Leu Leu Tyr Phe Lys Val Phe Gly Ile 
1               5                   


<210>  42
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  42

Ile Leu Ile Ser Lys Leu Leu Gly Ala 
1               5                   


<210>  43
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  43

Tyr Leu Leu Glu Lys Thr Arg Val Ala 
1               5                   


<210>  44
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  44

Ala Leu Asp Phe Lys Leu Ala Ala Ala 
1               5                   


<210>  45
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  45

Gln Leu Ala Leu Lys Val Glu Gly Val 
1               5                   


<210>  46
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  46

Phe Leu Lys Ile Lys Val Thr Ala Ala 
1               5                   


<210>  47
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  47

Ala Leu Leu Ala Lys Arg Leu Gly Ala 
1               5                   


<210>  48
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  48

Gly Leu Thr Phe Lys Gly Pro Gly Ala 
1               5                   


<210>  49
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  49

Tyr Ala Val Thr Lys Thr Asp Gly Ile 
1               5                   


<210>  50
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  50

Ile Phe Ile Asn Lys Leu Asn Gly Ala 
1               5                   


<210>  51
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  51

Ile Leu Lys Glu Lys Val His Val Gly 
1               5                   


<210>  52
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  52

Lys Val Leu Gly Lys Gly Ser Phe Gly 
1               5                   


<210>  53
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  53

Arg Thr Ser Gln Lys Gly Thr Val Ala 
1               5                   


<210>  54
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  54

Gln Ser Asp Pro Lys Pro Ala Val Ala 
1               5                   


<210>  55
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  55

Leu Phe Leu Pro Lys Leu Val Val Gly 
1               5                   


<210>  56
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  56

Ile Asp Pro Tyr Lys Glu Phe Gly Ala 
1               5                   


<210>  57
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  57

Ile Asp Thr Tyr Lys Glu Phe Gly Ala 
1               5                   


<210>  58
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  58

Phe Leu Ala Ile Lys Lys Leu Tyr Gly Val 
1               5                   10  


<210>  59
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  59

Asn Leu Leu Glu Lys Asp Tyr Phe Gly Leu 
1               5                   10  


<210>  60
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  60

Gly Leu Phe Gly Lys Thr Gln Val Gly Val 
1               5                   10  


<210>  61
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  61

Ser Leu Leu Phe Lys Thr Ser Val Gly Val 
1               5                   10  


<210>  62
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  62

Leu Leu Glu Gly Lys Val Leu Pro Gly Val 
1               5                   10  


<210>  63
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  63

Leu Leu Tyr Phe Lys Lys Val Phe Gly Ile 
1               5                   10  


<210>  64
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  64

Ala Leu Trp Ala Lys Ser Pro Gly Val Leu 
1               5                   10  


<210>  65
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  65

Phe Leu Lys Ile Lys Lys Val Thr Ala Ala 
1               5                   10  


<210>  66
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  66

Ala Leu Leu Ala Lys Lys Arg Leu Gly Ala 
1               5                   10  


<210>  67
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  67

Ala Ala Leu Lys Lys Ala Leu Ala Ala Ala 
1               5                   10  


<210>  68
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  68

Tyr Ala Val Thr Lys Lys Thr Asp Gly Ile 
1               5                   10  


<210>  69
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  69

Thr Thr Gly Leu Lys Pro Thr Val Ala Leu 
1               5                   10  


<210>  70
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Candidate peptide sequence

<400>  70

Lys Val Leu Gly Lys Gly Ser Phe Gly Lys 
1               5                   10  


